Fluvastatin inhibits mast cell degranulation without changing the cytoplasmic Ca2+ level

Area of Science:

• Pharmacology
• Immunology
• Cell Biology

Background:

• Mast cells play a crucial role in allergic reactions through degranulation.
• Statins are cholesterol-lowering drugs with potential anti-inflammatory effects.
• The impact of different statin types on mast cell degranulation requires further investigation.

Purpose of the Study:

• To evaluate the pharmacological effect of various statins on mast cell degranulation.
• To elucidate the mechanism behind statin-mediated inhibition of mast cell degranulation.

Main Methods:

• RBL-2H3 mast cells were stimulated with dinitrophenol-human serum albumin (DNP-HSA).
• Inhibition of degranulation was assessed using hydrophilic (pravastatin) and lipophilic statins (simvastatin, fluvastatin, atorvastatin).
• Mechanisms were explored using fluvastatin, mevalonic acid, and geranylgeranyl transferase inhibitors (GGTI-286, FPTIII), alongside calcium level and cell viability assays.

Main Results:

• Lipophilic statins (simvastatin, fluvastatin, atorvastatin) inhibited DNP-HSA-induced mast cell degranulation, with varying potency.
• Hydrophilic pravastatin did not show significant inhibitory effects.
• Inhibitory effects were reversed by mevalonic acid.
• Fluvastatin inhibited degranulation without affecting intracellular calcium release/influx, cell morphology, proliferation, or viability.
• Geranylgeranyl transferase inhibitor (GGTI-286) inhibited degranulation, but farnesyl transferase inhibitor (FPTIII) did not.
• GGTI-286's inhibition was independent of cytoplasmic calcium levels.

Conclusions:

• Lipophilic statins, particularly fluvastatin, inhibit mast cell degranulation.
• The mechanism involves suppression of geranylgeranyl transferase, likely via mevalonic acid depletion, rather than alterations in calcium signaling or cell viability.
• These findings suggest a potential therapeutic role for specific statins in mast cell-mediated inflammatory conditions.